Virtu KCG Holdings’s Arcturus Therapeutics ARCT Stock Holding History

Virtu KCG Holdings’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,966	Closed	-$16K	–	2855
2017 Q1	$16K	Sell	1,966 -3,063	-61%	-$28.4K	﹤0.01%	2993
2016 Q4	$74K	Sell	5,029 -1,748	-26%	-$26.1K	﹤0.01%	3003
2016 Q3	$117K	Buy	+6,777	New	+$219K	﹤0.01%	2587
2016 Q2	–	Sell	-3,533	Closed	-$94K	–	2928
2016 Q1	$94K	Buy	+3,533	New	+$120K	﹤0.01%	2344
2015 Q3	–	Sell	-3,277	Closed	-$150K	–	3315
2015 Q2	$150K	Buy	+3,277	New	+$150K	﹤0.01%	2749
2015 Q1	–	Sell	-2,020	Closed	-$53K	–	3112
2014 Q4	$53K	Sell	2,020 -20	-1%	-$636	﹤0.01%	3415
2014 Q3	$220K	Buy	+2,040	New	+$266K	﹤0.01%	2790

Other funds holding ARCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Virtu KCG Holdings's ARCT Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Arcturus Therapeutics (ARCT) in Q2 2017, closing a stake of 1,966 shares — an estimated $16K sold.

Virtu KCG Holdings first reported a position in ARCT in Q3 2014 and held it in 7 quarters. The position peaked at $220K in Q3 2014. 23 funds tracked by Wall St. Rank hold ARCT as of Q2 2017.

Virtu KCG Holdings reported no remaining Arcturus Therapeutics position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 1,966 Arcturus Therapeutics shares in Q2 2017, an estimated $16K.
Virtu KCG Holdings first reported a position in Arcturus Therapeutics in Q3 2014 and held it in 7 quarters.
Virtu KCG Holdings's Arcturus Therapeutics position peaked at $220K in Q3 2014.
23 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.